StockNews.AI
IONS
StockNews.AI
29 days

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

1. Positive Phase 3 results for donidalorsen show significant reduction in HAE attacks. 2. 84% of patients benefitted, enhancing prospects for IONS's HAE treatment market.

2m saved
Insight
Article

FAQ

Why Very Bullish?

The significant efficacy results suggest strong market potential and can drive up IONS stock, similar to past successes like Spinraza.

How important is it?

The article discusses crucial clinical trial results which are directly linked to IONS's product pipeline, impacting investor sentiment positively.

Why Long Term?

Long-term effects are anticipated as successful clinical results often lead to enhanced sales and market position over time.

Related Companies

VRTXALNY
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema (HAE) were published in The Journal of Allergy and Clinical Immunology (JACI) In Practice. Results indicate that patients who switched to donidalorsen from prior prophylactic treatments showed a 62% further reduction in mean monthly HAE attack rate from baseline, and 84% of p.

Related News